ADAP has been the subject of a number of other reports. Zacks Investment Research upgraded Adaptimmune Therapeutics from a hold rating to a buy rating and set a $5.75 target price for the company in a report on Monday, February 4th. SunTrust Banks lowered their target price on Adaptimmune Therapeutics to $12.00 and set a buy rating for the company in a report on Thursday, December 13th. Finally, ValuEngine cut Adaptimmune Therapeutics from a buy rating to a hold rating in a report on Wednesday, December 12th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $13.38.
Shares of NASDAQ ADAP traded down $0.17 during mid-day trading on Monday, reaching $4.23. 189,260 shares of the company’s stock were exchanged, compared to its average volume of 272,573. Adaptimmune Therapeutics has a 52-week low of $3.55 and a 52-week high of $14.63. The stock has a market cap of $444.94 million, a PE ratio of -4.41 and a beta of 1.31.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
See Also: Dividend
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.